MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

Oncopeptides AB ( ($SE:ONCO) ) just unveiled an update. Oncopeptides AB announced that a panel of multiple myeloma experts has endorsed the use of ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

Multiple myeloma survivor Ronald D. Chin, one of CURE’s contributing bloggers, shared a bit of his blood cancer journey in a recent vlog entry for CURE. Chin received a diagnosis of multiple myeloma ...

Broadcasting legend Sandy Roberts is celebrating a major win in the fight against cancer, with the federal government ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...